The development of an oral GLP-1 receptor agonist for the management of type 2 diabetes: evidence to date

Glucagon-like peptide 1 receptor agonists (GLP1-RA) are prominent agents in the therapeutics of type 2 diabetes mellitus due to their exemplary efficacy in both preprandial and postprandial glycemia, their safety, low risk of hypoglycemia, their multilevel pathophysiological superiority, weight loss...

Descripción completa

Detalles Bibliográficos
Autores principales: Antza, Christina, Nirantharakumar, Krishnarajah, Doundoulakis, Ioannis, Tahrani, Abd A, Toulis, Konstantinos A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709822/
https://www.ncbi.nlm.nih.gov/pubmed/31686781
http://dx.doi.org/10.2147/DDDT.S166765

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709822/
https://www.ncbi.nlm.nih.gov/pubmed/31686781
http://dx.doi.org/10.2147/DDDT.S166765

Ejemplares similares